Compare ETG & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETG | TWST |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | ETG | TWST |
|---|---|---|
| Price | $22.36 | $30.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $46.33 |
| AVG Volume (30 Days) | 132.1K | ★ 1.8M |
| Earning Date | 01-01-0001 | 02-02-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | N/A | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $14.08 | $23.30 |
| 52 Week High | $18.34 | $55.33 |
| Indicator | ETG | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 50.53 |
| Support Level | $22.27 | $31.19 |
| Resistance Level | $22.60 | $33.31 |
| Average True Range (ATR) | 0.30 | 1.66 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 83.57 | 52.18 |
Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.